Jazz Pharmaceuticals
JAZZ
403 hedge funds and large institutions have $9.34B invested in Jazz Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 69 funds opening new positions, 145 increasing their positions, 126 reducing their positions, and 41 closing their positions.
68% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 41
15% more repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 126
7% more funds holding
Funds holding: 376 → 403 (+27)
3% less capital invested
Capital invested by funds: $9.65B → $9.34B (-$309M)
1.3% less ownership
Funds ownership: 93.38% → 92.07% (-1.3%)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
57% less call options, than puts
Call options by funds: $29.5M | Put options by funds: $68.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$39.3M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$36.1M |
| 3 |
Bank of New York Mellon
New York
|
+$35.8M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$33M |
| 5 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
+$29.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$152M |
| 2 |
CCM
Cadian Capital Management
New York
|
-$125M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$102M |
| 4 |
Two Sigma Investments
New York
|
-$49.8M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$48.3M |
JAZZ Hedge Fund Activity: Q3 2018 in Review
403 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q3 2018, worth a combined $9.34B — down 3.2% from $9.65B a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new JAZZ positions and 41 closed out — a net gain of 28 holders — while 145 added to existing stakes and 126 trimmed.
The largest buyer was Westfield Capital Management, adding an estimated $39.3M. The largest seller was Fidelity Investments, cutting an estimated $152M.
- 403 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q3 2018, up from 376 in Q2 2018.
- Funds reported $9.34B of Jazz Pharmaceuticals stock for Q3 2018, down 3.2% quarter-over-quarter.
- 69 funds opened new Jazz Pharmaceuticals positions in Q3 2018 and 41 closed out, a net change of +28 holders.
- The largest Jazz Pharmaceuticals buyer in Q3 2018 was Westfield Capital Management, an estimated $39.3M added.
- The largest Jazz Pharmaceuticals seller in Q3 2018 was Fidelity Investments, an estimated $152M sold.
Based on aggregated 13F filings for Q3 2018.